₹12,111 Cr
27.10
₹447 Cr
As on 13-Aug-2024 IST
₹-13.55
•
-1.36%
₹998.60
₹998.00
₹1,037.05
₹970.65
4,90,138
₹596.00 - 1,037.05
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Glenmark Life
| 49.92 | 16.12 | 19.00 | 52.21 | 9.42 | -- | -- |
|
BSE Healthcare
| 30.05 | 6.86 | 18.26 | 46.79 | 16.31 | 26.45 | 12.81 |
|
BSE Small Cap
| 24.81 | -1.39 | 17.32 | 50.92 | 26.42 | 33.21 | 18.27 |
|
2023
|
2022
|
|
|---|---|---|
|
Glenmark Life
| 56.38 | -33.42 |
|
BSE Small Cap
| 47.52 | -1.80 |
|
BSE Healthcare
| 36.97 | -12.10 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Glenmark Life Sciences Ltd stood at ₹ 2,850 Cr as on 30-Jun-24
The share price of Glenmark Life Sciences Ltd is ₹985.05 (NSE) and ₹988.45 (BSE) as of 13-Aug-2024 IST. Glenmark Life Sciences Ltd has given a return of 9.42% in the last 3 years.
Glenmark Life Sciences Ltd has a market capitalisation of ₹ 12,111 Cr as on 13-Aug-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Glenmark Life Sciences Ltd is 4.96 times as on 13-Aug-2024, a 42% premium to its peers’ median range of 3.50 times.
The P/E ratio of Glenmark Life Sciences Ltd is 27.10 times as on 13-Aug-2024, a 43% discount to its peers’ median range of 47.46 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Glenmark Life Sciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Glenmark Life Sciences Ltd.
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Nirma Limited.
The promoters of Glenmark Life Sciences Ltd are NIRMA LIMITED and GLENMARK PHARMACEUTICALS LIMITED. They collectively own 82.84 per cent of the total equity. The chairman of the company is
The promoters of Glenmark Life Sciences Ltd have pledged 7.85% of the total equity as on Jun-24.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,248
|
|
|
7,943
|
|
|
4,730
|
|
|
3,967
|
| Glenmark Life Sciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
18.92
|
|
Operating margin(%)
|
25.52
|
|
Net Margin(%)
|
19.36
|
|
Dividend yield(%)
|
2.28
|
Yes, TTM profit after tax of Glenmark Life Sciences Ltd was ₹447 Cr.
₹12,111.35 Cr
₹2,293.38 Cr
₹446.92 Cr
₹301.59 Cr
₹0.00 Cr
82.85%
High
₹596.00 - 1,037.05
₹2.00
12,25,28,672
NSE: GLS, BSE: 543322
Solapur, Maharashtra
www.glenmarklifesciences.com
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril,... Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Nirma Limited. Read more
Stocks 
Glenmark Life Sciences Ltd.
Widely used:
